Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252312972 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Martina Bortolot und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins B-raf, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Although rare in non-small cell lung cancer (NSCLC), BRAF mutations present considerable therapeutic challenges. While the use of BRAF and MEK inhibitor combinations has significantly improved survival outcomes in patients with BRAF V600E mutations, no targeted therapies are currently available for class II and III mutations, leaving the optimal treatment strategy and prognosis for these patients uncertain. Additionally, despite immunotherapy typically showing limited benefit in patients with other activating genomic alterations, it appears to deliver comparable efficacy in BRAF-mutated NSCLC, emerging as a potentially viable treatment option, particularly in patients with a history of smoking. However, resistance to BRAF pathway inhibitors is inevitable, leading to disease progression, and a well-defined strategy to overcome these resistance mechanisms is lacking. This review aims to explore the critical challenges in the management of BRAF-mutated NSCLC, providing a comprehensive summary of the current evidence and highlighting ongoing clinical trials that aim to address these critical gaps.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
- Department of Medicine (DME), University of Udine, 33100 Udine, Italy.
ORCID-Profile: Sara Torresan, Elisa Bertoli, Brigida Stanzione, Alessandro Del Conte, Alessandra Bearz
Förderung
- Italian Ministry of Health
Zitieren
APA
Bortolot, M., Torresan, S., De Carlo, E., Bertoli, E., Stanzione, B., Del Conte, A., Spina, M., & Bearz, A. (2024). Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252312972
Vancouver
Bortolot M, Torresan S, De Carlo E, Bertoli E, Stanzione B, Del Conte A, et al. Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252312972
BibTeX
@article{Bortolot2024,
author = {Bortolot, Martina and Torresan, Sara and De Carlo, Elisa and Bertoli, Elisa and Stanzione, Brigida and Del Conte, Alessandro and Spina, Michele and Bearz, Alessandra},
title = {Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252312972}
}
EUVIMED